Borislava G. Pavlova
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Optimizing Development of Plain Language Summaries of Clinical Trial Results.
Journal: Health literacy research and practice
Published: September 04, 2026
Data privacy protection in scientific publications: process implementation at a pharmaceutical company.
Journal: BMC medical ethics
Published: March 09, 2022
Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B.
Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Published: August 21, 2020
Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
Journal: Pharmacology research & perspectives
Published: October 11, 2017
Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: March 25, 2016
Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes.
Journal: Expert review of clinical pharmacology
Published: February 10, 2015
Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: August 13, 2014
Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: February 15, 2014
Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326).
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: January 24, 2014
Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: June 14, 2013
Last Updated: 09/26/2026